230 related articles for article (PubMed ID: 34404444)
1. Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development.
Ye L; Wang L; Yang J; Hu P; Zhang C; Tong S; Liu Z; Tian D
J Transl Med; 2021 Aug; 19(1):352. PubMed ID: 34404444
[TBL] [Abstract][Full Text] [Related]
2. Identification of Tumor Antigens and Immune Landscape in Glioblastoma for mRNA Vaccine Development.
Ye L; Wang L; Yang J; Hu P; Zhang C; Tong S; Liu Z; Tian D
Front Genet; 2021; 12():701065. PubMed ID: 34527020
[No Abstract] [Full Text] [Related]
3. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
Front Immunol; 2021; 12():738435. PubMed ID: 34603319
[TBL] [Abstract][Full Text] [Related]
4. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
Front Immunol; 2022; 13():773264. PubMed ID: 35185876
[TBL] [Abstract][Full Text] [Related]
5. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
Huang X; Zhang G; Tang T; Liang T
Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
[TBL] [Abstract][Full Text] [Related]
6. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
Front Immunol; 2021; 12():709986. PubMed ID: 34512630
[TBL] [Abstract][Full Text] [Related]
7. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
[No Abstract] [Full Text] [Related]
8. Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development.
Chen Z; Wang X; Yan Z; Zhang M
Cancer Med; 2022 Jul; 11(13):2711-2726. PubMed ID: 35285582
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatics analyses for the identification of tumor antigens and immune subtypes of gastric adenocarcinoma.
Wei S; Sun Q; Chen J; Li X; Hu Z
Front Genet; 2022; 13():1068112. PubMed ID: 36579327
[No Abstract] [Full Text] [Related]
10. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.
Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY
Front Genet; 2022; 13():853113. PubMed ID: 35734437
[No Abstract] [Full Text] [Related]
11. Predictive Panel for Immunotherapy in Low-Grade Glioma.
Lv Q; Zhang Z; Fu H; Li D; Liu Y; Sun Y; Wu M
World Neurosurg; 2024 Mar; 183():e825-e837. PubMed ID: 38216032
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
You W; Ouyang J; Cai Z; Chen Y; Wu X
Front Immunol; 2022; 13():827506. PubMed ID: 35874675
[TBL] [Abstract][Full Text] [Related]
13. Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine.
Ping H; Yu W; Gong X; Tong X; Lin C; Chen Z; Cai C; Guo K; Ke H
Invest New Drugs; 2022 Dec; 40(6):1173-1184. PubMed ID: 35962880
[TBL] [Abstract][Full Text] [Related]
14. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
Wang F
Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
[TBL] [Abstract][Full Text] [Related]
15. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine.
Hu J; Mo Z
Math Biosci Eng; 2023 Jan; 20(2):2157-2182. PubMed ID: 36899527
[TBL] [Abstract][Full Text] [Related]
16. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
Huang X; Tang T; Zhang G; Liang T
Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
[TBL] [Abstract][Full Text] [Related]
17. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development.
Lu TL; Li CL; Gong YQ; Hou FT; Chen CW
World J Gastrointest Oncol; 2023 Oct; 15(10):1717-1738. PubMed ID: 37969406
[TBL] [Abstract][Full Text] [Related]
18. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
19. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
Hao YP; Wang WY; Qiao Q; Li G
Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
[TBL] [Abstract][Full Text] [Related]
20. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
Li Y; Feng Y; Luo F; Peng G; Li Y
Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
